<DOC>
	<DOCNO>NCT00042354</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . The purpose study determine whether Clofarabine safe effective treatment Acute Myelogenous Leukemia ( AML . )</brief_summary>
	<brief_title>Phase II Study Clofarabine Pediatric Acute Myelogenous Leukemia ( AML ) Patients</brief_title>
	<detailed_description>This non-randomized , open label , Phase II study Clofarabine pediatric patient refractory relapse acute myelogenous leukemia ( AML ) . Eligible patient must first subsequent relapse refractory . Forty eligible patient enrol Fleming 2-stage sequential study design order well ass efficacy safety clofarabine patient population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have diagnosis AML accord FAB classification great equal 25 % blast bone marrow . Be le equal 21 year old time initial diagnosis . Not eligible therapy higher curative potential , must first subsequent relapse and/or refractory . Where alternative therapy show prolong survival analogous population , offer patient prior discuss study . Patients acute promyelocytic leukemia ( M3 ) must treat least 2 regimensa retinoic acidcontaining regimen arsenic trioxidecontaining regimen consider study . Have Karnofsky Performance Status ( KPS ) great equal 70 . Provide sign , write informed consent parent guardian assent patient great equal 7 year old accord local IRB institutional requirement . Have adequate organ function indicate follow laboratory value , obtain within 2 week prior registration : Serum bilirubin less equal 1.5 x ULN ; AST ALT less equal 5 x ULN ; Serum Creatinine le 2 x ULN age . ULN= Institutional Upper Limit Normal Received previous treatment Clofarabine . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Are pregnant lactate . Male female patient fertile must agree use effective mean birth control ( i.e. , latex condom , diaphragm , cervical cap , etc ) avoid pregnancy . Have psychiatric disorder would interfere consent , study participation , follow . Are receive chemotherapy . Patients must previous therapy least 2 week ( exception intrathecal therapy , allow 24hrs prior 1st dose study drug ) must recover acute toxicity previous therapy prior enrollment . Treatment may start early , follow consultation ILEX Medical Monitor , evidence disease relapse prior time . Have severe concurrent disease , , judgment investigator , would make patient inappropriate entry study . Have symptomatic CNS involvement . Febrile neutropenia time study entry . Known suspected fungal infection ( ie . patient parenteral antifungal therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>CLO222</keyword>
	<keyword>clolar</keyword>
	<keyword>Pediatric Acute Myelogenous Leukemia</keyword>
</DOC>